[go: up one dir, main page]

CO2019001043A2 - Composición de cannabis - Google Patents

Composición de cannabis

Info

Publication number
CO2019001043A2
CO2019001043A2 CONC2019/0001043A CO2019001043A CO2019001043A2 CO 2019001043 A2 CO2019001043 A2 CO 2019001043A2 CO 2019001043 A CO2019001043 A CO 2019001043A CO 2019001043 A2 CO2019001043 A2 CO 2019001043A2
Authority
CO
Colombia
Prior art keywords
cancer
cannabis composition
pharmaceutical composition
relates
symptom associated
Prior art date
Application number
CONC2019/0001043A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019001043(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CO2019001043A2 publication Critical patent/CO2019001043A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un método para tratar el cáncer o un síntoma asociado con el cáncer. En particular, la presente invención se refiere a un método para tratar el cáncer o un síntoma asociado con el cáncer, que comprende administrar a un paciente que lo necesite una cantidad eficaz de la composición farmacéutica que comprende un extracto de Cannabis que comprende Δ9 tetrahidrocannabinol (THC) en una cantidad de desde 50 % a 99 % en peso de la composición farmacéutica.
CONC2019/0001043A 2016-08-03 2019-02-01 Composición de cannabis CO2019001043A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition
PCT/AU2017/050817 WO2018023166A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
CO2019001043A2 true CO2019001043A2 (es) 2020-06-19

Family

ID=65524553

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0001043A CO2019001043A2 (es) 2016-08-03 2019-02-01 Composición de cannabis

Country Status (15)

Country Link
US (2) US11304925B1 (es)
EP (1) EP3493800A4 (es)
JP (2) JP2019526541A (es)
KR (3) KR20190034576A (es)
CN (1) CN109789123A (es)
AU (4) AU2017305103B2 (es)
BR (1) BR112019001794A2 (es)
CA (1) CA3031300A1 (es)
CL (1) CL2019000266A1 (es)
CO (1) CO2019001043A2 (es)
IL (1) IL264458B (es)
MX (1) MX386086B (es)
PE (2) PE20200677A1 (es)
SG (1) SG11201900501RA (es)
WO (1) WO2018023166A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001852A2 (pt) 2016-08-03 2019-05-07 Zelda Therapeutics Operations Pty Ltd composição de cannabis
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
KR20200104278A (ko) 2017-06-19 2020-09-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 수면 장애 조성물 및 그의 치료
CA3103178A1 (en) * 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
JP2021500312A (ja) * 2017-09-15 2021-01-07 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 自閉症の治療のための組成物および方法
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
MX2020010603A (es) * 2018-04-09 2021-02-02 Ellevet Sciences Extracto de cáñamo para tratamiento de dolor en animales.
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
US11946016B2 (en) 2018-06-14 2024-04-02 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020084423A1 (en) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Extraction-based contract execution
CA3123773A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
NL2022615B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
JP7556882B2 (ja) * 2019-04-17 2024-09-26 ノルディックカン・アー／エス 速崩壊カンナビノイド錠剤
EP4041000A1 (en) * 2019-10-09 2022-08-17 Nicoventures Trading Limited Aerosolisable material
CN118161552A (zh) * 2019-12-19 2024-06-11 史蒂文·罗斯斯坦 富含多酚化合物的提取物以及相关方法
AU2021264109A1 (en) * 2020-04-29 2022-12-08 Ligar Limited Partnership Imprinted polymers and methods for their use
PE20230837A1 (es) * 2020-06-12 2023-05-19 Zelira Therapeutics Operations Pty Ltd Composicion y metodo para el tratamiento del dolor cronico
KR20220126653A (ko) * 2021-03-08 2022-09-16 주식회사 엘지생활건강 칸나비게롤을 포함하는 조성물
WO2022215071A1 (en) * 2021-04-05 2022-10-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Compositions and methods for the treatment of cancer
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2025231524A1 (en) * 2024-05-08 2025-11-13 Heyday RX Pty Ltd Cannabinoid compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US8628796B2 (en) 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
JP2015515977A (ja) * 2012-05-03 2015-06-04 エコ・ファーマシューティカルズ・ビー．ブイ．Ｅｃｈｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Δ９−テトラヒドロカンナビノールを含む大麻草単離物及びこのような単離物を製造するための方法
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
US9095554B2 (en) 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
SI3062606T1 (sl) 2013-10-29 2019-09-30 Biotech Institute, Llc Gojenje, priprava, predelava in uporaba posebnega kanabisa
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
EP3217995A1 (en) * 2014-08-25 2017-09-20 Janing Holding ApS Device with compositions for delivery to the lungs, the oral mucosa and the brain
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
EA201791299A1 (ru) * 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
WO2016105514A1 (en) * 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
BR112019001852A2 (pt) 2016-08-03 2019-05-07 Zelda Therapeutics Operations Pty Ltd composição de cannabis
SG11201900596XA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
NZ750272A (en) 2021-09-24
CL2019000266A1 (es) 2019-10-04
EP3493800A1 (en) 2019-06-12
KR102447510B1 (ko) 2022-09-27
IL264458B (en) 2021-06-30
WO2018023166A1 (en) 2018-02-08
KR20190034576A (ko) 2019-04-02
AU2021205115B2 (en) 2023-06-15
IL264458A (en) 2019-02-28
MX386086B (es) 2025-03-18
AU2019203529B2 (en) 2021-04-29
JP7139559B2 (ja) 2022-09-21
SG11201900501RA (en) 2019-02-27
AU2019203529A1 (en) 2019-06-06
KR20210129747A (ko) 2021-10-28
AU2017305103A1 (en) 2018-07-05
EP3493800A4 (en) 2020-04-08
MX2019001286A (es) 2019-06-13
KR20220132674A (ko) 2022-09-30
PE20230607A1 (es) 2023-04-13
JP2019526541A (ja) 2019-09-19
AU2018100920B4 (en) 2019-02-07
US20220202767A1 (en) 2022-06-30
AU2017305103B2 (en) 2019-02-21
JP2021054836A (ja) 2021-04-08
CA3031300A1 (en) 2018-02-08
CN109789123A (zh) 2019-05-21
BR112019001794A2 (pt) 2019-05-07
AU2021205115A1 (en) 2021-08-12
US11304925B1 (en) 2022-04-19
AU2018100920A4 (en) 2018-08-02
PE20200677A1 (es) 2020-06-11

Similar Documents

Publication Publication Date Title
CO2019001043A2 (es) Composición de cannabis
CL2019000268A1 (es) Composición de cannabis.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
CL2019000270A1 (es) Composición de cannabis.
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
BR112019000690A2 (pt) composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide
MX379255B (es) Uso de cannabinoides en el tratamiento de epilepsia.
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2020012800A (es) Cannabinoides y usos de los mismos.
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato